Live Analyst Rating Changes 4079 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Ryan Langston
TD
Ryan Langston
TD Cowen
Wall Street Analyst
★★★★★
#131
on 13Foresight · ranked by our own returns
71%
Success Rate
+26.3%
Average Return
20 of 28 calls profitable · +23.6% vs benchmark
🔒 5-year track record is Pro. Showing 1-year — upgrade.
📈 Across the calls we could measure, roughly 71% of Ryan Langston's ratings turned a profit when each position was held for 1 year — averaging +26.3% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

81 Buy 45 Hold 0 Sell
Ryan's Stock Coverage 20 ratings · 2026-06-30
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return
THC
Tenet Healthcare
 Jun 25, 2026 BUY Strong Buy
+15.8% avg upside
26 analysts
$233.00
24.57% Upside
 +1.8%
HCA
HCA Healthcare
 Jun 25, 2026 BUY Strong Buy
+9.1% avg upside
35 analysts
$431.00
9.76% Upside
 +1.2%
UHS
Universal Health
 Jun 22, 2026 BUY Buy
+43.6% avg upside
22 analysts
$197.00
34.02% Upside
 +1.3%
ADUS
Addus Homecare
 Jun 18, 2026 BUY Strong Buy
+31.6% avg upside
18 analysts
$131.00
33.52% Upside
 ·
EHC
Encompass Health
 Jun 16, 2026 BUY Strong Buy
+10.5% avg upside
22 analysts
$125.00
23.92% Upside
 +1.5%
SGRY
Surgery Partners
 May 27, 2026 BUY Strong Buy
+49.0% avg upside
18 analysts
$17.00
2.59% Upside
 +17.4%
PIII
P3 Health Partners
 May 22, 2026 HOLD Buy
+1610.6% avg upside
8 analysts
$14.00
17.20% Upside
 -7.3%
ASTH
Astrana Health
 May 12, 2026 BUY Strong Buy
+19.3% avg upside
16 analysts
$45.00
0.09% Downside
 +15.4%
DVA
DaVita
 May 11, 2026 HOLD Hold
-26.9% avg upside
17 analysts
$201.00
8.52% Downside
 +7.2%
PRVA
Privia Health Group
 May 11, 2026 BUY Strong Buy
+24.2% avg upside
26 analysts
$30.00
17.47% Upside
 +7.8%
ALHC
Alignment Healthcare
 May 04, 2026 BUY Strong Buy
-4.9% avg upside
19 analysts
$25.00
7.55% Upside
 +2.0%
CNC
Centene
 May 04, 2026 HOLD Buy
+2.8% avg upside
29 analysts
$47.00
27.18% Downside
 +22.7%
HUM
Humana
 May 01, 2026 HOLD Buy
-16.8% avg upside
34 analysts
$211.00
45.74% Downside
 +60.9%
MOH
Molina Healthcare
 Apr 24, 2026 HOLD Buy
-3.0% avg upside
26 analysts
$163.00
29.05% Downside
 +13.8%
ELV
Elevance Health
 Apr 24, 2026 BUY Strong Buy
+10.8% avg upside
32 analysts
$400.00
3.07% Upside
 +12.6%
ACHC
Acadia Healthcare
 Apr 24, 2026 BUY Strong Buy
+41.8% avg upside
17 analysts
$24.00
13.34% Downside
 +1.1%
UNH
UnitedHealth
 Apr 23, 2026 HOLD Strong Buy
-1.7% avg upside
36 analysts
$337.00
19.64% Downside
 +19.1%
AGL
Agilon Health
 Feb 27, 2026 HOLD Buy
-60.1% avg upside
26 analysts
$15.00
87.06% Downside
 +628.4%
CI
Cigna
 Nov 01, 2024 BUY Strong Buy
+24.0% avg upside
29 analysts
$391.00
40.28% Upside
 -21.3%
LFST
Lifestance Health Group
 Aug 09, 2024 HOLD Strong Buy
-5.9% avg upside
14 analysts
$7.00
32.25% Downside
 -22.0%
🔒 15 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Ryan Langston — Frequently Asked Questions
How accurate are Ryan Langston's stock ratings?
Based on the calls 13Foresight could measure, about 71% of Ryan's ratings were profitable over a one-year hold, with an average return of +26.3% per rating, or +23.6% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Ryan ranked on 13Foresight?
Ryan Langston is currently ranked #131 with a 5-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Ryan cover?
Ryan most recently has ratings on THC, HCA, UHS, ADUS, EHC, SGRY, PIII, ASTH, DVA, PRVA, ALHC, CNC and 8 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.